Go to content

Publications

350 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

International strategic agenda 2022-2023 National Health Care Institute

The international strategic agenda 2022-2023 describes the international activities of the National Health Care Institute ...

Publication | 21-04-2022

Package advice tisagenlecleucel (Kymriah®) for the treatment of r/r DLBCL

The National Health Care Institute has completed its reassessment whether tisagenlecleucel (Kymriah®) can be included in the ...

Report | 25-01-2022

Package advice acalabrutinib (Calquence®) for the treatment of chronic lymphatic leukaemia

The National Health Care Institute has completed its assessment whether acalabrutinib (Calquence®) can be included in the insured ...

Report | 17-01-2022

GVS advice on volanesorsen (Waylivra)

The National Health Care Institute advises the Minister to include volanesorsen on List 1B of the GVS. Volanesorsen (Waylivra®) ...

Report | 10-01-2022

Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS

The National Health Care Institute has completed its assessment whether ravulizumab (Ultomiris®) can be included in the insured ...

Report | 15-12-2021

GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis

The National Health Care Institute recommends the Minister to include tirbanibulin on List 1A in cluster 0D06BBADC V of the GVS. ...

Report | 01-12-2021

Package advice venetoclax (Venclyxto®)

The National Health Care Institute has completed its assessment whether venetoclax (Venclyxto®) can be included in the insured ...

Report | 10-11-2021

GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)

National Health Care Institute has completed its assessment whether ponesimod (Ponvory®) can be included in the ...

Report | 26-10-2021

Package advice cemiplimab (Libtayo®) for the treatment of non-small cell lung carcinoma (NSCLC)

Zorginstituut Nederland has completed its assessment whether cemiplimab (Libtayo®) as primary care treatment for stage IIIBC-IV ...

Report | 26-10-2021

GVS assessment empagliflozin (Jardiance®) for the treatment of adults with chronic heart failure

The National Health Care Institute recommends the Minister for Medical Care to extend the reimbursement condition of ...

Report | 21-10-2021

Go to